Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 0438 • ACR Convergence 2022
Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies
Khai-Tuan Andrew Bui¹, Rachel Richard², Ariane Drouin³, Nader Toban¹, Marianne Levesque⁴, Rosalie-Selene Meunier⁵, Carolyn Ross⁶ and Jean-Paul Makhzoum³, ¹Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ²Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Laval, QC, Canada, ³Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ⁴Division of Respirology, Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ⁵Hopital Sacre-Coeur, Universite de Montreal, Montréal, QC, Canada, ⁶University of Montreal, Montréal, QC, Canada
Background/Purpose: Various pulmonary manifestations may occur in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). ANCA-related interstitial lung disease (ILD) has recently been described in…
Abstract Number: 0454 • ACR Convergence 2022
Advantages and Disadvantages in Applying 2022 ACR/EULAR Classification Criteria to Conventionally Diagnosed Japanese GPA Patients
Ryo Kuwata¹, Yuko Shirota², Tsuyoshi Shirai³, Hiroyuki Yamashita¹, Hiroko Sato³, Tomoki Takeda², Yumiko Oka², Takao Kodera⁴, Hiroshi Kaneko¹, Junichi Kameoka⁵, Hiroshi Fujii³ and Tomonori Ishii⁶, ¹Division of Rheumatic diseases, National Center for Global Health and Medicine, Tokyo, Japan, ²Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ³Department of Rheumatology, Tohoku University Hospital, Sendai, Japan, ⁴Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ⁵Divison of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ⁶Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan
Background/Purpose: The Chapel Hill Consensus Conference and the European Medicines Agency algorithm were commonly used to diagnose patients with granulomatosis with polyangiitis (GPA) 1）. Recently…
Abstract Number: 1075 • ACR Convergence 2022
Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype
Benjamin Terrier¹, David Jayne², Bernhard Hellmich³, Jane Bentley⁴, Jonathan Steinfeld⁵, Steven Yancey⁶, Namhee Kwon⁷, Praveen Akuthota⁸, Paneez Khoury⁹, Lee Baylis¹⁰ and Michael Wechsler¹¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²University of Cambridge, Cambridge, United Kingdom, ³Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, ⁴Clinical Statistics, GlaxoSmithKline, Brentford, United Kingdom, ⁵Clinical Sciences, Respiratory, GSK (affiliation at time of research), Philadelphia, PA, ⁶Respiratory Therapeutic Area, GSK (affiliation at the time of research), Research Triangle Park, NC, ⁷Clinical Sciences, Respiratory, GSK, Brentford, United Kingdom, ⁸Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California, San Diego, CA, ⁹Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Global Medical Affairs, GlaxoSmithKline, Durham, NC, ¹¹Department of Medicine, National Jewish Health, Denver, CO
Background/Purpose: Patients with eosinophilic granulomatosis with polyangiitis (EGPA) can have vasculitic or eosinophilic phenotypes. The MIRRA study demonstrated that patients with EGPA spent more time…
Abstract Number: 1092 • ACR Convergence 2022
Intrarenal Synthesis of Complement C3 Localized to Distinct Vascular Compartments in ANCA-associated Renal Vasculitis
Désirée Tampe, Samy Hakroush and Björn Tampe, University Medical Center Göttingen, Göttingen, Germany
Background/Purpose: The activation of the complement system contributes essentially to its pathogenesis by autoantibody-antigen recognition directed against host cells in anti-neutrophil cytoplasmic antibody (ANCA)-associated renal…
Abstract Number: 0439 • ACR Convergence 2022
Clinical Characteristics of Patients with ANCA-Associated Vasculitis with and Without Alpha-1 Antitrypsin Deficiency Alleles
Lynn Fussner¹, David Cuthbertson², Peter Grayson³, David Jayne⁴, Carol McAlear⁵, Michael Walsh⁶, Katherine Siminovitch⁷, Ulrich Specks⁸ and Peter Merkel⁹, ¹The Ohio State University, Columbus, OH, ²University of South Florida, Tampa, FL, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴University of Cambridge, Cambridge, United Kingdom, ⁵Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Mayo Clinic, Rochester, MN, ⁹University of Pennsylvania, Philadelphia, PA
Background/Purpose: There are multiple reasons to suspect that alpha-1 antitrypsin (A1AT) genotype impacts disease characteristics in ANCA-associated vasculitis (AAV). A1AT serves as the predominant endogenous…
Abstract Number: 0455 • ACR Convergence 2022
Performance of 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Turkish Vasculitis Patients
Ummugulsum Gazel¹, Sevinc Can Sandikci², Ahmet Omma³, Sinem Burcu Kocaer⁴, Fatoş Onen⁵, Onay Gercik⁶, Servet Akar⁷, Kerem Abacar⁸, Ebru Asicioglu⁹, Serhan Tuglular⁹, Fatma Alibaz-Oner⁸ and Haner Direskeneli¹⁰, ¹University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, ²Ankara Numune Education and Research Hospital, Rheumatology, Ankara, Turkey, ³Ankara Numune Education and Research Hospital, Rheumatology, Ankara, Turkey, Istanbul, Turkey, ⁴Dokuz Eylul University, Faculty of Medicine, Rheumatology, Izmir, Turkey, ⁵Dokuz Eylul University, Faculty of Medicine, Rheumatology, İzmir, Turkey, ⁶Izmir Tepecik Research Hospital, Izmir, Turkey, ⁷Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁸Marmara University, Rheumatology, Istanbul, Turkey, ⁹Marmara University, Faculty of Medicine, Nephrology, Istanbul, Turkey, ¹⁰Marmara University, Rheumatology, Istanbul, Istanbul, Turkey
Background/Purpose: The American College of Rheumatology (ACR)-1990 criteria is the most used method for the classification of ANCA Associated Vasculitis (AAV). However, with ACR-1990 criteria,…
Abstract Number: 1076 • ACR Convergence 2022
ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain
Naomi Patel¹, David Jayne², Peter Merkel³, Pirow Bekker⁴, yuqing zhang⁵, Huibin Yue⁴ and John Stone⁶, ¹Massachusetts General Hospital, Sale Creek, TN, ²University of Cambridge, Cambridge, United Kingdom, ³University of Pennsylvania, Philadelphia, PA, ⁴ChemoCentryx, San Juan Capistrano, CA, ⁵Massachusetts General Hospital, Quincy, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: The ADVOCATE trial (Jayne DRW et al, N Engl J Med, 2021) was a randomized, double-blind, controlled trial of avacopan vs prednisone in addition…
Abstract Number: 1093 • ACR Convergence 2022
ANCA Associated Vasculitis: Online CME Improves Rheumatologists’ Knowledge and Confidence
Natalie Guevara¹, James Martorano¹ and Karen Badal², ¹Medscape Education, New York, NY, ²Medscape, New York, NY
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) is a rare condition that affects several organ systems, has a high rate of mortality, and involves clinicians…
Abstract Number: 0440 • ACR Convergence 2022
COVID-19 in Patients with ANCA Associated Vasculitis – Single Center Experience
Alojzija Hocevar¹, Matija Tomšič² and Ziga Rotar¹, ¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ²UMC Ljubljana, LJUBLJANA, Slovenia
Background/Purpose: In patients with ANCA associated vasculitis (AAV) a higher mortality rate due to COVID-19 has been observed compared to general population. We aimed to…
Abstract Number: 0456 • ACR Convergence 2022
Application of Adult ACR/EULAR 2022 Classification Criteria in Pediatric Vasculitis Patients
Else Bosman¹, Kimberly Morishita² and David Cabral³, ¹University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia - Vancouver, Vancouver, BC, Canada, ³BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Previous classification of childhood vasculitis used 1990 ACR criteria for classifying granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA),. In 2008, EULAR/PRINTO/PRES…
Abstract Number: 1077 • ACR Convergence 2022
Safety of Avacopan in ANCA-Associated Vasculitis: Combined Data from Three Clinical Trials
Pirow Bekker¹, Peter Merkel² and David Jayne³, ¹ChemoCentryx, San Juan Capistrano, CA, ²U of Pennsylvania, Philadelphia, PA, ³University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Avacopan is approved as adjunctive treatment for adults with ANCA-associated vasculitis (AAV). This study aimed to combine and report on data of the safety…
Abstract Number: 1202 • ACR Convergence 2022
Clinical Profile and Trend of Vasculitis in Patients with Acute Coronary Syndrome – Insight from National Database 2010 to 2019
Palak Shah¹, Ana Arevalo², Rasha Alaameri³, Brinda Basida⁴, Urja Nagadia⁵, Sanket Basida⁵, shobhana Chaudhari⁶ and Monil Majmundar⁷, ¹Metropolitan Hospital Center, New York Medical College, New York, NY, ²University of Chicago, Chicago, IL, ³New York Medical College/ Metropolitan Program, New York, NY, ⁴DMC/Sinai Grace Hospital, Detroit, MI, ⁵University of Missouri, Columbia, MO, ⁶NYC Health and Hospital/Metropolitan Hospital, New York, NY, ⁷University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Vasculitides are characterized by inflammation of vessel walls with reactive damage to mural structures leading to compromise of the lumen. Vasculitides also accelerate atherosclerosis…
Abstract Number: L14 • ACR Convergence 2021
Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis
David Jayne¹, Peter Merkel², Annette Bruchfeld³, Duvuru Geetha⁴, Alexandre Karras⁵, John Niles⁶ and Pirow Bekker⁷, ¹University of Cambridge, Cambridge, United Kingdom, ²University of Pennsylvania, Philadelphia, PA, ³Linköping University, Linköping, Sweden, ⁴Johns Hopkins University, Baltimore, MD, ⁵Hopital Europeen Georges Pompidou, Paris, France, ⁶Massachusetts General Hospital, Boston, MA, ⁷ChemoCentryx, Inc., San Carlos, CA
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is a life- or organ-threatening condition in which patients experience severe inflammation of small blood vessels; renal disease is…
Abstract Number: 0425 • ACR Convergence 2021
Diagnostic Accuracy of Muscle MRI for Muscular Vasculitis in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis: A Pilot Study
Ryuta Inaba, Daisuke Waki, Keisuke Nishimura, Tomohiro Yoshida, Kaoru Mizukawa, Shintaro Yamamoto, Osamu Iri, Kohei Yo and Hiroyuki Murabe, Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan
Background/Purpose: Histopathologic confirmation is the golden standard for diagnosis of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), but sometimes can be difficult because of its invasion (e.g.…
Abstract Number: 0953 • ACR Convergence 2021
An International Delphi Exercise to Identify Items of Importance for Measuring Response to Treatment for ANCA-associated Vasculitis
Kaitlin Quinn¹, Sara Monti², Georgia Lanier³, Maria Bjork Viðarsdóttir⁴, Robin Christensen⁵, David R.W. Jayne⁶, Carol Langford⁷, Alfred Mahr⁸, Christian Pagnoux⁹, Gunnar Tomasson¹⁰ and Peter Merkel¹¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²University of Pavia, Pavia, Italy, ³n/a, Sherborn, MA, ⁴n/a, Reykjavik, Iceland, ⁵Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸Kantonsspital St. Gallen, St.Gallen, Switzerland, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰University of Iceland, Reykjavik, Iceland, ¹¹University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) is characterized by fluctuating levels of disease activity. Randomized controlled trials (RCTs) in AAV have used multiple instruments to define active…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].